Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
复制标题
DOI：
10.1126/scitranslmed.3001713
复制
发表时间：
2011-03-09
影响因子：
17.1
通讯作者：
Ho, Dean
中科院分区：
文献类型：
--
作者：
Chow, Edward K.;Zhang, Xue-Qing;Ho, Dean
通过改善药物递送来提高化疗效率将有助于治疗化学抗性癌症，例如复发性乳腺肿瘤和肝癌。改善药物递送的一种方法是通过使用纳米金刚石（ND）疗法，其既可扩展又具有生物相容性。在这里，我们研究了ND结合化疗药物在肝癌和乳腺癌小鼠模型中的疗效。ND和阿霉素（Dox）的复合物（NDX）克服了药物外排，并显着增加细胞凋亡和肿瘤生长抑制超过常规的Dox治疗在小鼠肝癌和乳腺癌模型。未修饰的Dox治疗代表了大多数癌症治疗方案的临床标准，并且与标准Dox治疗相比，NDX具有显著降低的体内毒性。因此，ND偶联化疗是一种有前途的，生物相容性的策略，克服化疗耐药性和提高化疗的疗效和安全性。
Enhancing chemotherapeutic efficiency through improved drug delivery would facilitate treatment of chemoresistant cancers, such as recurrent mammary tumors and liver cancer. One way to improve drug delivery is through the use of nanodiamond (ND) therapies, which are both scalable and biocompatible. Here, we examined the efficacy of an ND-conjugated chemotherapeutic in mouse models of liver and mammary cancer. A complex (NDX) of ND and doxorubicin (Dox) overcame drug efflux and significantly increased apoptosis and tumor growth inhibition beyond conventional Dox treatment in both murine liver tumor and mammary carcinoma models. Unmodified Dox treatment represents the clinical standard for most cancer treatment regimens, and NDX had significantly decreased toxicity in vivo compared to standard Dox treatment. Thus, ND-conjugated chemotherapy represents a promising, biocompatible strategy for overcoming chemoresistance and enhancing chemotherapy efficacy and safety.